The United States Food and Drug Administration has granted marketing clearance to the first over-the-counter continuous glucose monitor approved for children, allowing families to purchase a wearable blood-sugar tracking device for kids as young as two years old without requiring a doctor's prescription.
The FDA announced on June 13, 2026 (Philippine Time) that it had cleared Dexcom Inc.'s Stelo Glucose Biosensor System for individuals two years of age and older who do not use insulin. The decision expands a device the agency originally cleared for adults 18 and older in March 2024, when Stelo became the first over-the-counter continuous glucose monitor, or CGM, ever authorized in the United States.
The clearance covers children with diabetes managed through oral medication, as well as children without a diabetes diagnosis whose families wish to monitor how diet, exercise, and lifestyle habits affect glucose levels. The device is explicitly not intended for individuals who use insulin to manage their condition.
FDA Director Cites Commitment to Pediatric Innovation
Dr. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, issued a statement emphasizing the agency's intent to expand access to health management tools for younger patients.
"Children deserve access to the best tools available to manage their health," Dr. Tarver said, adding that the clearance reflected the agency's commitment to "fostering innovation for pediatric patients and supporting the safe and effective use of medical devices where children live, learn, and play."
The statement positioned the decision as part of a broader regulatory effort to bring consumer-grade health monitoring technology to populations previously underserved by over-the-counter medical devices.
Regulators Cite Growing Prediabetes Crisis Among American Children
The FDA framed its clearance decision as a direct public health response to a rising problem in the United States. Prediabetes is increasingly affecting children across the country, placing millions at heightened risk of progressing to Type 2 diabetes, the agency said in its announcement.
Over-the-counter CGMs can address that risk for young users who do not take insulin, regulators said. By delivering real-time glucose data, devices like Stelo are designed to help children and their caregivers build what the agency described as "glycemic awareness" — an understanding of how their bodies respond to meals, physical activity, and other daily factors.
The product is indicated for children with diabetes who take oral medication, as well as for those without a formal diagnosis whose families want greater insight into how everyday habits affect blood sugar levels. The FDA said such early awareness could support healthier long-term outcomes.
How the Stelo Wearable Sensor Operates
The Stelo system uses a wearable sensor placed on the skin, paired with a compatible smartphone application, to continuously measure, record, analyze, and display glucose values in real time. The app can be installed on a parent's or caregiver's phone, allowing adults to monitor a child's glucose trends remotely.
Each Stelo sensor is designed to last up to 15 days before requiring replacement. However, the FDA noted that actual wear time may run shorter in children than in adults due to a combination of physiological and behavioral factors unique to pediatric users.
The app refreshes glucose measurements and trend data every 15 minutes, providing a near-continuous picture of a child's blood sugar patterns throughout the day and night. The FDA stressed that users and caregivers should consult a health care provider before making any medication adjustments based on readings from the device.
Real-World Evidence Used to Support Pediatric Authorization
According to the FDA, the pediatric clearance drew on a combination of data sources to support its decision. Dexcom and the agency combined earlier clinical study data from both children and adults with real-world data on current integrated CGM use across both groups, in order to gauge how the device would perform in pediatric users over the full 15-day wear period.
This approach — blending prospective clinical trial data with real-world evidence — reflects a regulatory methodology the FDA has increasingly applied to device authorizations, particularly where gathering large-scale pediatric trial data presents logistical or ethical challenges.
The integration of real-world data was considered sufficient to demonstrate the device's safety and effectiveness profile for children across the intended use population, according to the agency's announcement.
Cautions and Safety Warnings Attached to the Clearance
The FDA attached several important cautions to the pediatric authorization. For children, the device must be used under the supervision of an adult caregiver at all times.
The Stelo system is not designed for people with problematic hypoglycemia — dangerously low blood sugar — because the device does not include alerts for that condition. It is also not intended for people on dialysis. The FDA additionally stated that individuals with a history of disordered eating or eating disorders should speak with a health care provider before using the device.
Participants in earlier clinical studies reported mild adverse events associated with the sensor, including local infection, skin irritation, and pain or discomfort at the application site, according to the agency.
The FDA was explicit that Stelo data should be used as a supplementary tool in consultation with medical professionals — not as a standalone guide to treatment or medication decisions.
Dexcom's Stelo Expands a Market It Pioneered in 2024
Dexcom's original Stelo clearance in March 2024 opened the United States market to non-prescription CGMs — a category that had historically been restricted to people managing diabetes under a physician's supervision. The clearance was widely regarded as a landmark moment in consumer health technology, making real-time glucose monitoring accessible to a much broader population.
The technology reads glucose from interstitial fluid just beneath the skin, as opposed to drawing blood samples through finger-prick testing. Since the 2024 authorization, other manufacturers have entered the consumer wellness and over-the-counter CGM space, intensifying competition in the segment.
Dexcom has previously stated that the Stelo platform was built specifically for non-insulin users, offering a 15-day sensor wear period and a cash-pay pricing option, making it accessible to consumers without a prescription drug benefit.
Clearance Aligned With FDA's 'Home as Health Hub' Initiative
The FDA said the pediatric clearance aligns with its Home as a Health Care Hub Initiative, a regulatory program focused on advancing patient-centered medical devices designed to fit more seamlessly into daily life outside clinical settings.
The initiative reflects a broader shift in FDA policy toward enabling more health monitoring and management to occur in home environments, reducing dependence on in-clinic testing for conditions that can be tracked with wearable or consumer-grade technology.
With the latest clearance, the over-the-counter CGM market formally extends to children — a development the FDA described as meeting families where they are. The agency emphasized, however, that the data produced by Stelo should be interpreted and acted upon in partnership with licensed medical professionals, rather than used independently to guide treatment decisions.
The Stelo Glucose Biosensor System for children is now authorized for marketing in the United States as of the date of the FDA's announcement. Families considering the device for a child are advised to consult a licensed health care provider prior to use.
Photo credit: Photo from FDA.gov / Dexcom Inc.